What is it about?
This report summarizes the thinking of our second CNS Anticancer Drug Discovery & Development Conference. The stimulus for these conference was the dearth of new drugs available for patients with cancers that invade the CNS. This summary document addresses the many opportunities and problems that face investigators and pharmaceutical/biotech companies that are necessary if we are to see progress for people who develop these tumors.
Featured Image
Why is it important?
Aside from alkylating agents, no drugs with a different action have been approved for the treatment of primary and secondary CNS tumors in the past 40 years.
Perspectives
I believe that the problems we face in new drug development for these rare tumors are scientific, financial, regulatory, and societal in nature. The solution needed for new drugs to be created and marketed will require fresh thinking and new financial commitments.
Victor Levin
Read the Original
This page is a summary of: CNS Anticancer Drug Discovery and Development: 2016 conference insights, CNS Oncology, July 2017, Future Medicine,
DOI: 10.2217/cns-2017-0014.
You can read the full text:
Contributors
The following have contributed to this page
